Pfizer Inc | search
Click here to view Pfizer Inc news from 60+ newspapers.
Bookmark or Share- Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA ...NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY ® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.
- U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the ...HYMPAVZI is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for the treatment of hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via a pre-filled, auto-injector pen.
- Contact Us - PfizerGet the Answers to Your Questions. If you experience any unexpected side effects from one of our drugs, first tell your healthcare provider and then report it to us. This helps us track the safety of our medicines with more accuracy. If you are a journalist researching Pfizer, you may contact us directly.
- Press Releases - PfizerU.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors. 10.10.2024.
- Pfizer: One of the world's premier biopharmaceutical companiesClinical Trial Innovation: Putting the Patient First in Clinical Trial Design. Learn how Pfizer is making clinical trials more patient-friendly with easier enrollment, focus on patient experience, and data return initiatives. Read More.
More
